TABLE 2.
Serology data of the study participants at the different visits
| Visit according to cohort (mo) | LUMINEX serology (IgG, IgM, IgA against S, S2, RBD, N-FL, and N-Cterm) |
|||
|---|---|---|---|---|
| No. positive (%) | No. indeterminate (%) | No. negative (%) | No. missing (%) | |
| Barcelona | ||||
| M0 | 80 (13.8) | 51 (8.8) | 447 (77.3) | 0 (0) |
| M1 | 83 (14.7) | 59 (10.4) | 422 (74.7) | 1 (0.2) |
| M3a | 44 (62.9) | 4 (5.7) | 15 (21.4) | 7 (10.0) |
| M6 | 85 (16.8) | 35 (6.9) | 387 (76.3) | 0 (0) |
| Munich | ||||
| M0 | 133 (61) | 14 6.4) | 53 (24.3) | 18 (8.3) |
| M1 | 45 (77.6) | 3 (5.2) | 9 (15.5) | 1 (1.7) |
| M2 | 52 (75.4) | 6 (8.7) | 9 (13) | 2 (2.9) |
| M3 | 77 (82.8) | 4 (4.3) | 12 (12.9) | 0 (0) |
| M6 | 26 (54.2) | 3 (6.3) | 4 (8.3) | 15 (31.2) |
a
Only participants with any previous evidence of SARS-CoV-2 infection were invited to participate at study M3 (8). M, month.